Clinical trials: Large B Cell Diffuse Lymphoma
Lymphoma
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00028717
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 13 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Lymphoma
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer…
- Trial name
- NCT00863369
- Testing
- rituximab, bortezomib, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non-Hodgkin lymphoma (NHL) relapsed…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular
- Trial name
- NCT03357627
- Testing
- TAK-659, Venetoclax
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 43 people
- Sponsor
- Calithera Biosciences, Inc
Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
This phase II trial studies the side effects and how well bortezomib and vorinostat work in treating patients with non-Hodgkin lymphoma (NHL) after patients' own stem cell (autologous) transplant.
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00992446
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Neoplasms
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
Arginine methylation mediated by protein arginine methyl-transferases (PRMTs) is an important post-translational modification of proteins involved in a diverse range of cellular processes.
- Trial name
- NCT03666988
- Testing
- GSK3368715
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
- Trial name
- MATCH (NCT05354362)
- Testing
- ATG-010 and ATG-008
- Where
- 6 sites in China
- Volunteers
- 7 people
- Sponsor
- Antengene Corporation
Leukemia, Lymphoma
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus.
- Trial name
- NCT00002956
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Diffuse Large B Cell Lymphoma, Solid Tumor Cancer
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies.
- Trial name
- MOSAIC (NCT06625203)
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 7,000 people
- Sponsor
- OWKIN
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.
Leukemia, Lymphoma
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00044954
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- 14 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00042913
- Testing
- epratuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
DLBCL
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma *To evaluate best objective response rate (ORR)
- Trial name
- NCT07709624
- Testing
- Minjuvi
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- TTY Biopharm
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT02570542
- Testing
- leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan
- Where
- 14 sites in United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer
- Trial name
- NCT05153330
- Testing
- BMF-219
- Where
- 41 sites in United States, Greece and 3 more
- Volunteers
- 55 people
- Sponsor
- Biomea Fusion Inc.
Diffuse Large B-Cell Lymphoma (DLBCL)
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
- Trial name
- NCT07078500
- Testing
- orelabrutinib combined with the Pola-R-CHP regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B-cell Lymphoma
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
This study is to evaluate the efficacy and safety of Bortezomib plus GDP in the treatment of non-GCB DLBCL patients.
- Trial name
- NCT02542111
- Testing
- Bortezomib, Gemcitabine, Dexamethasone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
- Trial name
- NCT01693614
- Testing
- Buparlisib
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B Cell Lymphoma
A Study of ICP-022 in Patients With R/R DLBCL
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL.
- Trial name
- DLBCL (NCT04438005)
- Testing
- ICP-022
- Where
- 7 sites in China
- Volunteers
- 3 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
- Conditions
- Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01239875
- Testing
- dendritic cell vaccine therapy, cryotherapy, pneumococcal polyvalent vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.